HomeHealthcare & Life Sciences PCSK9-Targeted Therapy Market

Global PCSK9-Targeted Therapy Market Size, Share & Trends Analysis Report By Drug Type / Modality (Monoclonal Antibodies (mAbs) Alirocumab Evolocumab , siRNA-based Therapies Inclisiran , Gene Editing and Other Novel Modalities CRISPR-based approaches Antisense oligonucleotides (ASOs) ), By Indication  (Heterozygous Familial Hypercholesterolemia (HeFH) , Atherosclerotic Cardiovascular Disease (ASCVD) , Homozygous Familial Hypercholesterolemia (HoFH) , Hyperlipidemia (Non-FH) ), By Co

Starting From
USD 3950
Buy Now

Report Benefits

  • Develop business strategies by understanding the trends shaping and driving the Market.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.

  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

  • Track sales in the global and country-specific Market.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

  1. Executive Summary
    1. Introduction
  2. Market Introduction
    1. Market Definition
    2. Scope of the Study
    3. Market Structure
  3. Research Methodology
    1. Primary Research
    2. Research Methodology
    3. Assumptions & Exclusions
    4. Secondary Data Sources
  4. Market Factor Analysis
    1. Value Chain Analysis: PCSK9-Targeted Therapy Market
    2. Porters Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitution
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Dynamics
    1. Drivers
    2. Restraints
    3. Opportunities
  6. Recent Trends Analysis
  7. Impact of COVID-19 on PCSK9-Targeted Therapy Market
    1. Pre and Post Covid -19 Market Scenario Analysis
    2. Market Recovery Timeline and Challenge
    3. Measures Taken by Top Players
  8. Regulatory Landscape
  9. PCSK9-Targeted Therapy Market, By Drug Type / Modality
    1. Introduction
      1. Market Size and Forecast, By Drug Type / Modality
    2. Monoclonal Antibodies (mAbs) 
      1. Market Size and Forecast, By Region
      2. Alirocumab 
        1. Market Size and Forecast, By Region
      3. Evolocumab 
        1. Market Size and Forecast, By Region
    3. siRNA-based Therapies 
      1. Market Size and Forecast, By Region
      2. Inclisiran 
        1. Market Size and Forecast, By Region
    4. Gene Editing and Other Novel Modalities 
      1. Market Size and Forecast, By Region
      2. CRISPR-based approaches 
        1. Market Size and Forecast, By Region
      3. Antisense oligonucleotides (ASOs) 
        1. Market Size and Forecast, By Region
  10. PCSK9-Targeted Therapy Market, By Indication 
    1. Introduction
      1. Market Size and Forecast, By Indication 
    2. Heterozygous Familial Hypercholesterolemia (HeFH) 
      1. Market Size and Forecast, By Region
    3. Atherosclerotic Cardiovascular Disease (ASCVD) 
      1. Market Size and Forecast, By Region
    4. Homozygous Familial Hypercholesterolemia (HoFH) 
      1. Market Size and Forecast, By Region
    5. Hyperlipidemia (Non-FH) 
      1. Market Size and Forecast, By Region
  11. PCSK9-Targeted Therapy Market, By Route of Administration
    1. Introduction
      1. Market Size and Forecast, By Route of Administration
    2. Subcutaneous Injection 
      1. Market Size and Forecast, By Region
    3. Intravenous Injection 
      1. Market Size and Forecast, By Region
    4. Oral (in pipeline) 
      1. Market Size and Forecast, By Region
  12. PCSK9-Targeted Therapy Market, By Distribution Channel
    1. Introduction
      1. Market Size and Forecast, By Distribution Channel
    2. Hospital Pharmacies 
      1. Market Size and Forecast, By Region
    3. Retail Pharmacies 
      1. Market Size and Forecast, By Region
    4. Online Pharmacies 
      1. Market Size and Forecast, By Region
  13. PCSK9-Targeted Therapy Market, By Patient Type
    1. Introduction
      1. Market Size and Forecast, By Patient Type
    2. Primary Prevention (High Risk, No History of ASCVD) 
      1. Market Size and Forecast, By Region
    3. Secondary Prevention (With History of ASCVD) 
      1. Market Size and Forecast, By Region
    4. Statin-Intolerant Patients 
      1. Market Size and Forecast, By Region
  14. Regional Overview
    1. Introduction
      1. Market Size and Forecast
    2. North America
      1. Market Size and Forecast
        1. By Drug Type / Modality
          1. Monoclonal Antibodies (mAbs) 
            1. Alirocumab 
              1. Evolocumab 
              2. siRNA-based Therapies 
                1. Inclisiran 
                2. Gene Editing and Other Novel Modalities 
                  1. CRISPR-based approaches 
                    1. Antisense oligonucleotides (ASOs) 
                  2. By Indication 
                    1. Heterozygous Familial Hypercholesterolemia (HeFH) 
                      1. Atherosclerotic Cardiovascular Disease (ASCVD) 
                        1. Homozygous Familial Hypercholesterolemia (HoFH) 
                          1. Hyperlipidemia (Non-FH) 
                          2. By Route of Administration
                            1. Subcutaneous Injection 
                              1. Intravenous Injection 
                                1. Oral (in pipeline) 
                                2. By Distribution Channel
                                  1. Hospital Pharmacies 
                                    1. Retail Pharmacies 
                                      1. Online Pharmacies 
                                      2. By Patient Type
                                        1. Primary Prevention (High Risk, No History of ASCVD) 
                                          1. Secondary Prevention (With History of ASCVD) 
                                            1. Statin-Intolerant Patients 
                                          2. U.S.
                                            1. By Drug Type / Modality
                                              1. Monoclonal Antibodies (mAbs) 
                                                1. Alirocumab 
                                                  1. Evolocumab 
                                                  2. siRNA-based Therapies 
                                                    1. Inclisiran 
                                                    2. Gene Editing and Other Novel Modalities 
                                                      1. CRISPR-based approaches 
                                                        1. Antisense oligonucleotides (ASOs) 
                                                      2. By Indication 
                                                        1. Heterozygous Familial Hypercholesterolemia (HeFH) 
                                                          1. Atherosclerotic Cardiovascular Disease (ASCVD) 
                                                            1. Homozygous Familial Hypercholesterolemia (HoFH) 
                                                              1. Hyperlipidemia (Non-FH) 
                                                              2. By Route of Administration
                                                                1. Subcutaneous Injection 
                                                                  1. Intravenous Injection 
                                                                    1. Oral (in pipeline) 
                                                                    2. By Distribution Channel
                                                                      1. Hospital Pharmacies 
                                                                        1. Retail Pharmacies 
                                                                          1. Online Pharmacies 
                                                                          2. By Patient Type
                                                                            1. Primary Prevention (High Risk, No History of ASCVD) 
                                                                              1. Secondary Prevention (With History of ASCVD) 
                                                                                1. Statin-Intolerant Patients 
                                                                              2. Canada
                                                                            2. Europe
                                                                              1. Market Size and Forecast
                                                                                1. By Drug Type / Modality
                                                                                  1. Monoclonal Antibodies (mAbs) 
                                                                                    1. Alirocumab 
                                                                                      1. Evolocumab 
                                                                                      2. siRNA-based Therapies 
                                                                                        1. Inclisiran 
                                                                                        2. Gene Editing and Other Novel Modalities 
                                                                                          1. CRISPR-based approaches 
                                                                                            1. Antisense oligonucleotides (ASOs) 
                                                                                          2. By Indication 
                                                                                            1. Heterozygous Familial Hypercholesterolemia (HeFH) 
                                                                                              1. Atherosclerotic Cardiovascular Disease (ASCVD) 
                                                                                                1. Homozygous Familial Hypercholesterolemia (HoFH) 
                                                                                                  1. Hyperlipidemia (Non-FH) 
                                                                                                  2. By Route of Administration
                                                                                                    1. Subcutaneous Injection 
                                                                                                      1. Intravenous Injection 
                                                                                                        1. Oral (in pipeline) 
                                                                                                        2. By Distribution Channel
                                                                                                          1. Hospital Pharmacies 
                                                                                                            1. Retail Pharmacies 
                                                                                                              1. Online Pharmacies 
                                                                                                              2. By Patient Type
                                                                                                                1. Primary Prevention (High Risk, No History of ASCVD) 
                                                                                                                  1. Secondary Prevention (With History of ASCVD) 
                                                                                                                    1. Statin-Intolerant Patients 
                                                                                                                  2. U.K.
                                                                                                                    1. By Drug Type / Modality
                                                                                                                      1. Monoclonal Antibodies (mAbs) 
                                                                                                                        1. Alirocumab 
                                                                                                                          1. Evolocumab 
                                                                                                                          2. siRNA-based Therapies 
                                                                                                                            1. Inclisiran 
                                                                                                                            2. Gene Editing and Other Novel Modalities 
                                                                                                                              1. CRISPR-based approaches 
                                                                                                                                1. Antisense oligonucleotides (ASOs) 
                                                                                                                              2. By Indication 
                                                                                                                                1. Heterozygous Familial Hypercholesterolemia (HeFH) 
                                                                                                                                  1. Atherosclerotic Cardiovascular Disease (ASCVD) 
                                                                                                                                    1. Homozygous Familial Hypercholesterolemia (HoFH) 
                                                                                                                                      1. Hyperlipidemia (Non-FH) 
                                                                                                                                      2. By Route of Administration
                                                                                                                                        1. Subcutaneous Injection 
                                                                                                                                          1. Intravenous Injection 
                                                                                                                                            1. Oral (in pipeline) 
                                                                                                                                            2. By Distribution Channel
                                                                                                                                              1. Hospital Pharmacies 
                                                                                                                                                1. Retail Pharmacies 
                                                                                                                                                  1. Online Pharmacies 
                                                                                                                                                  2. By Patient Type
                                                                                                                                                    1. Primary Prevention (High Risk, No History of ASCVD) 
                                                                                                                                                      1. Secondary Prevention (With History of ASCVD) 
                                                                                                                                                        1. Statin-Intolerant Patients 
                                                                                                                                                      2. Germany
                                                                                                                                                      3. France
                                                                                                                                                      4. Spain
                                                                                                                                                      5. Italy
                                                                                                                                                      6. Russia
                                                                                                                                                      7. Nordic
                                                                                                                                                      8. Benelux
                                                                                                                                                      9. Rest of Europe
                                                                                                                                                    2. APAC
                                                                                                                                                      1. Market Size and Forecast
                                                                                                                                                        1. By Drug Type / Modality
                                                                                                                                                          1. Monoclonal Antibodies (mAbs) 
                                                                                                                                                            1. Alirocumab 
                                                                                                                                                              1. Evolocumab 
                                                                                                                                                              2. siRNA-based Therapies 
                                                                                                                                                                1. Inclisiran 
                                                                                                                                                                2. Gene Editing and Other Novel Modalities 
                                                                                                                                                                  1. CRISPR-based approaches 
                                                                                                                                                                    1. Antisense oligonucleotides (ASOs) 
                                                                                                                                                                  2. By Indication 
                                                                                                                                                                    1. Heterozygous Familial Hypercholesterolemia (HeFH) 
                                                                                                                                                                      1. Atherosclerotic Cardiovascular Disease (ASCVD) 
                                                                                                                                                                        1. Homozygous Familial Hypercholesterolemia (HoFH) 
                                                                                                                                                                          1. Hyperlipidemia (Non-FH) 
                                                                                                                                                                          2. By Route of Administration
                                                                                                                                                                            1. Subcutaneous Injection 
                                                                                                                                                                              1. Intravenous Injection 
                                                                                                                                                                                1. Oral (in pipeline) 
                                                                                                                                                                                2. By Distribution Channel
                                                                                                                                                                                  1. Hospital Pharmacies 
                                                                                                                                                                                    1. Retail Pharmacies 
                                                                                                                                                                                      1. Online Pharmacies 
                                                                                                                                                                                      2. By Patient Type
                                                                                                                                                                                        1. Primary Prevention (High Risk, No History of ASCVD) 
                                                                                                                                                                                          1. Secondary Prevention (With History of ASCVD) 
                                                                                                                                                                                            1. Statin-Intolerant Patients 
                                                                                                                                                                                          2. China
                                                                                                                                                                                            1. By Drug Type / Modality
                                                                                                                                                                                              1. Monoclonal Antibodies (mAbs) 
                                                                                                                                                                                                1. Alirocumab 
                                                                                                                                                                                                  1. Evolocumab 
                                                                                                                                                                                                  2. siRNA-based Therapies 
                                                                                                                                                                                                    1. Inclisiran 
                                                                                                                                                                                                    2. Gene Editing and Other Novel Modalities 
                                                                                                                                                                                                      1. CRISPR-based approaches 
                                                                                                                                                                                                        1. Antisense oligonucleotides (ASOs) 
                                                                                                                                                                                                      2. By Indication 
                                                                                                                                                                                                        1. Heterozygous Familial Hypercholesterolemia (HeFH) 
                                                                                                                                                                                                          1. Atherosclerotic Cardiovascular Disease (ASCVD) 
                                                                                                                                                                                                            1. Homozygous Familial Hypercholesterolemia (HoFH) 
                                                                                                                                                                                                              1. Hyperlipidemia (Non-FH) 
                                                                                                                                                                                                              2. By Route of Administration
                                                                                                                                                                                                                1. Subcutaneous Injection 
                                                                                                                                                                                                                  1. Intravenous Injection 
                                                                                                                                                                                                                    1. Oral (in pipeline) 
                                                                                                                                                                                                                    2. By Distribution Channel
                                                                                                                                                                                                                      1. Hospital Pharmacies 
                                                                                                                                                                                                                        1. Retail Pharmacies 
                                                                                                                                                                                                                          1. Online Pharmacies 
                                                                                                                                                                                                                          2. By Patient Type
                                                                                                                                                                                                                            1. Primary Prevention (High Risk, No History of ASCVD) 
                                                                                                                                                                                                                              1. Secondary Prevention (With History of ASCVD) 
                                                                                                                                                                                                                                1. Statin-Intolerant Patients 
                                                                                                                                                                                                                              2. South Korea
                                                                                                                                                                                                                              3. Japan
                                                                                                                                                                                                                              4. India
                                                                                                                                                                                                                              5. Australia
                                                                                                                                                                                                                              6. Singapore
                                                                                                                                                                                                                              7. Taiwan
                                                                                                                                                                                                                              8. South East Asia
                                                                                                                                                                                                                              9. Rest of Asia-Pacific
                                                                                                                                                                                                                            2. Middle East and Africa
                                                                                                                                                                                                                              1. Market Size and Forecast
                                                                                                                                                                                                                                1. By Drug Type / Modality
                                                                                                                                                                                                                                  1. Monoclonal Antibodies (mAbs) 
                                                                                                                                                                                                                                    1. Alirocumab 
                                                                                                                                                                                                                                      1. Evolocumab 
                                                                                                                                                                                                                                      2. siRNA-based Therapies 
                                                                                                                                                                                                                                        1. Inclisiran 
                                                                                                                                                                                                                                        2. Gene Editing and Other Novel Modalities 
                                                                                                                                                                                                                                          1. CRISPR-based approaches 
                                                                                                                                                                                                                                            1. Antisense oligonucleotides (ASOs) 
                                                                                                                                                                                                                                          2. By Indication 
                                                                                                                                                                                                                                            1. Heterozygous Familial Hypercholesterolemia (HeFH) 
                                                                                                                                                                                                                                              1. Atherosclerotic Cardiovascular Disease (ASCVD) 
                                                                                                                                                                                                                                                1. Homozygous Familial Hypercholesterolemia (HoFH) 
                                                                                                                                                                                                                                                  1. Hyperlipidemia (Non-FH) 
                                                                                                                                                                                                                                                  2. By Route of Administration
                                                                                                                                                                                                                                                    1. Subcutaneous Injection 
                                                                                                                                                                                                                                                      1. Intravenous Injection 
                                                                                                                                                                                                                                                        1. Oral (in pipeline) 
                                                                                                                                                                                                                                                        2. By Distribution Channel
                                                                                                                                                                                                                                                          1. Hospital Pharmacies 
                                                                                                                                                                                                                                                            1. Retail Pharmacies 
                                                                                                                                                                                                                                                              1. Online Pharmacies 
                                                                                                                                                                                                                                                              2. By Patient Type
                                                                                                                                                                                                                                                                1. Primary Prevention (High Risk, No History of ASCVD) 
                                                                                                                                                                                                                                                                  1. Secondary Prevention (With History of ASCVD) 
                                                                                                                                                                                                                                                                    1. Statin-Intolerant Patients 
                                                                                                                                                                                                                                                                  2. UAE
                                                                                                                                                                                                                                                                    1. By Drug Type / Modality
                                                                                                                                                                                                                                                                      1. Monoclonal Antibodies (mAbs) 
                                                                                                                                                                                                                                                                        1. Alirocumab 
                                                                                                                                                                                                                                                                          1. Evolocumab 
                                                                                                                                                                                                                                                                          2. siRNA-based Therapies 
                                                                                                                                                                                                                                                                            1. Inclisiran 
                                                                                                                                                                                                                                                                            2. Gene Editing and Other Novel Modalities 
                                                                                                                                                                                                                                                                              1. CRISPR-based approaches 
                                                                                                                                                                                                                                                                                1. Antisense oligonucleotides (ASOs) 
                                                                                                                                                                                                                                                                              2. By Indication 
                                                                                                                                                                                                                                                                                1. Heterozygous Familial Hypercholesterolemia (HeFH) 
                                                                                                                                                                                                                                                                                  1. Atherosclerotic Cardiovascular Disease (ASCVD) 
                                                                                                                                                                                                                                                                                    1. Homozygous Familial Hypercholesterolemia (HoFH) 
                                                                                                                                                                                                                                                                                      1. Hyperlipidemia (Non-FH) 
                                                                                                                                                                                                                                                                                      2. By Route of Administration
                                                                                                                                                                                                                                                                                        1. Subcutaneous Injection 
                                                                                                                                                                                                                                                                                          1. Intravenous Injection 
                                                                                                                                                                                                                                                                                            1. Oral (in pipeline) 
                                                                                                                                                                                                                                                                                            2. By Distribution Channel
                                                                                                                                                                                                                                                                                              1. Hospital Pharmacies 
                                                                                                                                                                                                                                                                                                1. Retail Pharmacies 
                                                                                                                                                                                                                                                                                                  1. Online Pharmacies 
                                                                                                                                                                                                                                                                                                  2. By Patient Type
                                                                                                                                                                                                                                                                                                    1. Primary Prevention (High Risk, No History of ASCVD) 
                                                                                                                                                                                                                                                                                                      1. Secondary Prevention (With History of ASCVD) 
                                                                                                                                                                                                                                                                                                        1. Statin-Intolerant Patients 
                                                                                                                                                                                                                                                                                                      2. Turky
                                                                                                                                                                                                                                                                                                      3. Saudi Arabia
                                                                                                                                                                                                                                                                                                      4. South Africa
                                                                                                                                                                                                                                                                                                      5. Egypt
                                                                                                                                                                                                                                                                                                      6. Nigeria
                                                                                                                                                                                                                                                                                                      7. Rest of MEA
                                                                                                                                                                                                                                                                                                    2. LATAM
                                                                                                                                                                                                                                                                                                      1. Market Size and Forecast
                                                                                                                                                                                                                                                                                                        1. By Drug Type / Modality
                                                                                                                                                                                                                                                                                                          1. Monoclonal Antibodies (mAbs) 
                                                                                                                                                                                                                                                                                                            1. Alirocumab 
                                                                                                                                                                                                                                                                                                              1. Evolocumab 
                                                                                                                                                                                                                                                                                                              2. siRNA-based Therapies 
                                                                                                                                                                                                                                                                                                                1. Inclisiran 
                                                                                                                                                                                                                                                                                                                2. Gene Editing and Other Novel Modalities 
                                                                                                                                                                                                                                                                                                                  1. CRISPR-based approaches 
                                                                                                                                                                                                                                                                                                                    1. Antisense oligonucleotides (ASOs) 
                                                                                                                                                                                                                                                                                                                  2. By Indication 
                                                                                                                                                                                                                                                                                                                    1. Heterozygous Familial Hypercholesterolemia (HeFH) 
                                                                                                                                                                                                                                                                                                                      1. Atherosclerotic Cardiovascular Disease (ASCVD) 
                                                                                                                                                                                                                                                                                                                        1. Homozygous Familial Hypercholesterolemia (HoFH) 
                                                                                                                                                                                                                                                                                                                          1. Hyperlipidemia (Non-FH) 
                                                                                                                                                                                                                                                                                                                          2. By Route of Administration
                                                                                                                                                                                                                                                                                                                            1. Subcutaneous Injection 
                                                                                                                                                                                                                                                                                                                              1. Intravenous Injection 
                                                                                                                                                                                                                                                                                                                                1. Oral (in pipeline) 
                                                                                                                                                                                                                                                                                                                                2. By Distribution Channel
                                                                                                                                                                                                                                                                                                                                  1. Hospital Pharmacies 
                                                                                                                                                                                                                                                                                                                                    1. Retail Pharmacies 
                                                                                                                                                                                                                                                                                                                                      1. Online Pharmacies 
                                                                                                                                                                                                                                                                                                                                      2. By Patient Type
                                                                                                                                                                                                                                                                                                                                        1. Primary Prevention (High Risk, No History of ASCVD) 
                                                                                                                                                                                                                                                                                                                                          1. Secondary Prevention (With History of ASCVD) 
                                                                                                                                                                                                                                                                                                                                            1. Statin-Intolerant Patients 
                                                                                                                                                                                                                                                                                                                                          2. Brazil
                                                                                                                                                                                                                                                                                                                                            1. By Drug Type / Modality
                                                                                                                                                                                                                                                                                                                                              1. Monoclonal Antibodies (mAbs) 
                                                                                                                                                                                                                                                                                                                                                1. Alirocumab 
                                                                                                                                                                                                                                                                                                                                                  1. Evolocumab 
                                                                                                                                                                                                                                                                                                                                                  2. siRNA-based Therapies 
                                                                                                                                                                                                                                                                                                                                                    1. Inclisiran 
                                                                                                                                                                                                                                                                                                                                                    2. Gene Editing and Other Novel Modalities 
                                                                                                                                                                                                                                                                                                                                                      1. CRISPR-based approaches 
                                                                                                                                                                                                                                                                                                                                                        1. Antisense oligonucleotides (ASOs) 
                                                                                                                                                                                                                                                                                                                                                      2. By Indication 
                                                                                                                                                                                                                                                                                                                                                        1. Heterozygous Familial Hypercholesterolemia (HeFH) 
                                                                                                                                                                                                                                                                                                                                                          1. Atherosclerotic Cardiovascular Disease (ASCVD) 
                                                                                                                                                                                                                                                                                                                                                            1. Homozygous Familial Hypercholesterolemia (HoFH) 
                                                                                                                                                                                                                                                                                                                                                              1. Hyperlipidemia (Non-FH) 
                                                                                                                                                                                                                                                                                                                                                              2. By Route of Administration
                                                                                                                                                                                                                                                                                                                                                                1. Subcutaneous Injection 
                                                                                                                                                                                                                                                                                                                                                                  1. Intravenous Injection 
                                                                                                                                                                                                                                                                                                                                                                    1. Oral (in pipeline) 
                                                                                                                                                                                                                                                                                                                                                                    2. By Distribution Channel
                                                                                                                                                                                                                                                                                                                                                                      1. Hospital Pharmacies 
                                                                                                                                                                                                                                                                                                                                                                        1. Retail Pharmacies 
                                                                                                                                                                                                                                                                                                                                                                          1. Online Pharmacies 
                                                                                                                                                                                                                                                                                                                                                                          2. By Patient Type
                                                                                                                                                                                                                                                                                                                                                                            1. Primary Prevention (High Risk, No History of ASCVD) 
                                                                                                                                                                                                                                                                                                                                                                              1. Secondary Prevention (With History of ASCVD) 
                                                                                                                                                                                                                                                                                                                                                                                1. Statin-Intolerant Patients 
                                                                                                                                                                                                                                                                                                                                                                              2. Mexico
                                                                                                                                                                                                                                                                                                                                                                              3. Argentina
                                                                                                                                                                                                                                                                                                                                                                              4. Chile
                                                                                                                                                                                                                                                                                                                                                                              5. Colombia
                                                                                                                                                                                                                                                                                                                                                                              6. Rest of LATAM
                                                                                                                                                                                                                                                                                                                                                                          3. Competitive Landscape, 2025
                                                                                                                                                                                                                                                                                                                                                                            1. Introduction
                                                                                                                                                                                                                                                                                                                                                                            2. PCSK9-Targeted Therapy Market Share Analysis, 2025 (%)
                                                                                                                                                                                                                                                                                                                                                                              1. Market Share Analysis, 2025
                                                                                                                                                                                                                                                                                                                                                                              2. Competition Ranking, 2025
                                                                                                                                                                                                                                                                                                                                                                              3. Key Developments & Growth Strategies
                                                                                                                                                                                                                                                                                                                                                                                1. Merger & Acquisition
                                                                                                                                                                                                                                                                                                                                                                                2. Product Launch
                                                                                                                                                                                                                                                                                                                                                                                3. Expansion
                                                                                                                                                                                                                                                                                                                                                                              4. Consolidated SWOT Analysis of Key Players
                                                                                                                                                                                                                                                                                                                                                                          4. Company Profile
                                                                                                                                                                                                                                                                                                                                                                            1. Amgen Inc.
                                                                                                                                                                                                                                                                                                                                                                              1. Business Overview
                                                                                                                                                                                                                                                                                                                                                                              2. Financial Data
                                                                                                                                                                                                                                                                                                                                                                              3. Key Product Categories
                                                                                                                                                                                                                                                                                                                                                                              4. Recent Developments
                                                                                                                                                                                                                                                                                                                                                                            2. Novartis AG
                                                                                                                                                                                                                                                                                                                                                                            3. Sanofi
                                                                                                                                                                                                                                                                                                                                                                            4. Regeneron Pharmaceuticals, Inc.
                                                                                                                                                                                                                                                                                                                                                                            5. Merck & Co., Inc.
                                                                                                                                                                                                                                                                                                                                                                            6. Eli Lilly and Company
                                                                                                                                                                                                                                                                                                                                                                            7. Verve Therapeutics
                                                                                                                                                                                                                                                                                                                                                                            8. AstraZeneca PLC
                                                                                                                                                                                                                                                                                                                                                                            9. Ionis Pharmaceuticals, Inc.
                                                                                                                                                                                                                                                                                                                                                                            10. Silence Therapeutics plc
                                                                                                                                                                                                                                                                                                                                                                            11. Arrowhead Pharmaceuticals, Inc.
                                                                                                                                                                                                                                                                                                                                                                            12. Alnylam Pharmaceuticals, Inc.